This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Universiteit Hasselt, University of Ghent. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2019
Title: Tom Artois: Innovator in Carcinogenic Detection
Introduction
Tom Artois is a notable inventor based in Diepenbeek, Belgium. He has made significant contributions to the field of carcinogenicity prediction through his innovative research. His work focuses on developing methods to detect non-genotoxic carcinogens, which is crucial for public health and safety.
Latest Patents
Tom Artois holds 1 patent for his invention titled "Methods to detect non-genotoxic carcinogens using flatworms." This patent discloses methods for predicting the carcinogenicity of various compounds. More specifically, it outlines techniques to determine whether a compound is a non-genotoxic carcinogen and to differentiate between genotoxic and non-genotoxic carcinogens based on in vivo stem cell proliferation patterns in flatworms.
Career Highlights
Throughout his career, Tom has worked with prestigious institutions, including the University of Ghent and Universiteit Hasselt. His research has contributed to a better understanding of carcinogenic compounds and their effects on living organisms.
Collaborations
Tom has collaborated with several professionals in his field, including Karen Smeets and An-Sofie Stevens. These partnerships have enhanced the quality and impact of his research.
Conclusion
Tom Artois is a pioneering inventor whose work in detecting non-genotoxic carcinogens has the potential to significantly advance public health initiatives. His innovative methods and collaborations reflect his commitment to scientific progress and safety.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile